Updated Jul 16, 2026
Savitz Ryan has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $15.90M.
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-13 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 5.6K | $101.97 | $568K |
| 2026-07-13 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 15.3K | $101.24 | $1.55M |
| 2026-07-13 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 10.4K | $100.22 | $1.04M |
| 2026-07-13 | DNTH | Dianthus Therapeutics, Inc. /DE/ | M — Option exercise [10b5-1] | 31.2K | $21.77 | $680K |
| 2026-04-10 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 8.2K | $89.84 | $739K |
| 2026-04-10 | DNTH | Dianthus Therapeutics, Inc. /DE/ | M — Option exercise [10b5-1] | 8.2K | $17.88 | $147K |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 7.2K | $85.54 | $619K |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 19.5K | $84.57 | $1.65M |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 59.8K | $83.90 | $5.02M |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 2.4K | $82.84 | $196K |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 800 | $81.36 | $65K |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 1.5K | $80.25 | $119K |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 21.8K | $78.86 | $1.72M |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 1.4K | $78.33 | $109K |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | M — Option exercise [10b5-1] | 40.0K | $17.88 | $715K |
| 2026-04-01 | DNTH | Dianthus Therapeutics, Inc. /DE/ | M — Option exercise [10b5-1] | 74.4K | $8.44 | $628K |
| 2025-12-06 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 20.0K | $45.18 | $904K |
| 2025-12-06 | DNTH | Dianthus Therapeutics, Inc. /DE/ | M — Option exercise [10b5-1] | 20.0K | $8.44 | $169K |
| 2025-12-05 | DNTH | Dianthus Therapeutics, Inc. /DE/ | S — Open-market sale [10b5-1] | 20.0K | $45.18 | $904K |
| 2025-12-05 | DNTH | Dianthus Therapeutics, Inc. /DE/ | M — Option exercise [10b5-1] | 20.0K | $8.44 | $169K |
Savitz Ryan is a corporate insider — currently tracked as Insider of Dianthus Therapeutics, Inc. /DE/ (DNTH). InsiderAlpha tracks every SEC Form 4 filing in real time.
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 15 open-market sales ($15.90M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Savitz Ryan profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.